Last deal

$10M

Amount

Series A

Stage

26.07.2023

Date

3

all rounds

$50M

Total amount

date founded

Financing round

General

About Company
AsclepiX Therapeutics is a biotech company that develops novel therapeutics for retinal diseases and cancer.

Industry

Sector :

Subsector :

Keywords :

Also Known As

AsclepiX

founded date

01.01.2011

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

Using bioinformatics and systems biology methods, AsclepiX Therapeutics designs short biomimetic anti-angiogenic and anti-lymphangiogenic peptides, as well as biodegradable nano and microparticles for drug delivery, to treat diseases in ophthalmology, oncology, and other angiogenesis and lymphangiogenesis-dependent diseases. Their lead program, AXT107, is in Ph1/2a clinical trials and targets multiple pathways to prevent neovascularization and reduce vascular permeability in patients with retinal diseases.
Contacts

Contact Email

Social url

Legal Names

Legal name

AsclepiX Therapeutics, Inc.
Similar Companies
1000
Certa Therapeutics

Certa Therapeutics

Cura Therapeutics is a biotechnology company that develops drugs to treat fibrotic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Dandenong Rd, Melbourne VIC, Australia

total rounds

1

total raised

$19.13M
Enleofen Bio Pte Ltd

Enleofen Bio Pte Ltd

Enleofen is a biotech company that develops antibody therapeutics for fibro-inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Singapore

total rounds

1
Synspira

Synspira

Synspira Therapeutics develops treatments for cystic fibrosis and rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA

total rounds

3

total raised

$25.24M
Athersys

Athersys

Athersys is a biotechnology company focused on developing regenerative medicine therapies for various medical conditions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cleveland, OH, USA

total rounds

9

total raised

$208.9M

Financials

Funding Rounds
3
3

Number of Funding Rounds

$50M

Money Raised

Their latest funding was raised on 26.07.2023. Their latest investor Hibiscus Capital Management. Their latest round Series A

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Perceptive Advisors

Perceptive Advisors

Perceptive Advisors is a privately owned hedge fund sponsor that finances global public equity markets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance, Venture Capital

Location

New York, NY, USA

count Of Investments

256

count Of Exists

20
Perceptive Advisors

Perceptive Advisors

Perceptive Advisors is a privately owned hedge fund sponsor that finances global public equity markets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance, Venture Capital

Location

New York, NY, USA

count Of Investments

256

count Of Exists

20

Barer & Son Capital

Barer & Son Capital is a venture capital firm focused on investing in the healthcare and life science sector.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Health Care, Financial Services

Location

Mendham Township, NJ, USA

count Of Investments

4

count Of Exists

1
Co-Investors
Investors
8
2

Number of lead investors

8

Number of investors

Investor 
Lead 
Round 
Partners 
Hibiscus Capital Management

Hibiscus Capital Management

Hibiscus Capital Management is a subsidiary of a biotechnology company focused on commercially viable technologies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

count Of Investments

2
Perceptive Advisors

Perceptive Advisors

Perceptive Advisors is a privately owned hedge fund sponsor that finances global public equity markets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance, Venture Capital

Location

New York, NY, USA

count Of Investments

256

count Of Exists

20
Rapha Capital Management

Rapha Capital Management

Rapha Capital Management is a venture capital firm that invests in revolutionary ideas in medicine, healthcare and technology.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Florida, NY, USA

count Of Investments

7

People

Founders
2
Jordan J. Green
Jordan J. Green

Jordan J. Green

Jordan Green is also an Associate Professor of Biomedical Engineering, Ophthalmology, Oncology, Neurosurgery, and Materials Science & Engineering at the Johns Hopkins University School of Medicine. He is an executive committee member of the Institute for NanoBioTechnology, co-founder of the Translational Tissue Engineering Center at JHU, and part of the Wilmer Eye Institute and the Sydney Kimmel Comprehensive Cancer. He has strong expertise in nanotechnology, biomaterials, and drug delivery that includes doctoral and postdoctoral training at MIT with Institute Professor Robert Langer and consulting/collaborative work with biotechnology companies. He has published over 70 scientific papers in these areas as well as 12 issued or pending patents. He has received numerous honors including the Maryland Outstanding Young Engineer Award, the Biomedical Engineering Society Rita Schaffer Award, the American Institute of Chemical Engineers Nanoscale Science & Engineering Forum Young Investigator Award, the American Society for Gene & Cell Therapy Outstanding New Investigator Award, the Allan P. Colburn Award for Excellence in Publications by the American Institute of Chemical Engineers, the Presidential Early Career Award for Scientists and Engineers, and was named by Baltimore Business Journal as one of the “40 Under 40” and by Popular Science as one of the “Brilliant Ten.” Dr. Green has given more than 65 invited national/international talks and has served on national grant panels for the National Institutes of Health, the National Science Foundation, and the Department of Defense. His work on angiogenesis and on drug delivery has been supported by grants from the National Institutes of Health, the Maryland Technology Development Corporation, the Coulter Foundation, and the Edward N. and Della L. Thome Memorial Foundation, Award in Age-Related Macular Degeneration Research.

current job

The Johns Hopkins University
The Johns Hopkins University

organization founded

1

Jordan J. Green

Aleksander Popel
Aleksander Popel

Aleksander Popel

Aleksander S. Popel is also a Professor of Biomedical Engineering at the Johns Hopkins University School of Medicine. He holds joint appointments as Professor of Oncology in the School of Medicine, and Professor of Chemical & Biomolecular Engineering in the Johns Hopkins Whiting School of Engineering. He is a member of the Institute for Nanobiotechnology, In Vivo Cellular Molecular Imaging Center, and the Sydney Kimmel Comprehensive Cancer Center. His areas of expertise are angiogenesis and microcirculation, systems biology, computational medicine & biology. He published over 300 scientific papers in these areas. He served as a Visiting Professor at MIT and Harvard University. He is the recipient of the Eugene M. Landis Award from the Microcirculatory Society. He delivered keynote addresses for The Virtual Physiological Human (VPH) European Union Physiome Project and Next-Generation Integrated Simulation of Living Matter Project in Japan; he was C. Forbes Dewey Distinguished Lecturer in Biological Engineering at the Massachusetts Institute of Technology, delivered A.C. Suhren Lecture at Tulane University, Robert M. and Mary Haythornthwaite Distinguished Lecturer at Temple University, and Kawasaki Medical Society Lecturer in Japan. He is a Fellow of the American Institute of Medical and Biological Engineering, American Heart Association, American Physiological Society, and American Society of Mechanical Engineers, and an Inaugural Fellow of the Biomedical Engineering Society. He has been a member of editorial boards of biological and biomedical engineering journals. He served in an advisory role to biotech and pharmaceutical companies. He regularly serves on grant review boards and advisory panels at the National Institutes of Health, National Science Foundation, and other US and international funding agencies. His work on angiogenesis at the Johns Hopkins University has been supported by grants from the National Institutes of Health, the Safeway Breast Cancer Foundation, the Maryland Technology Development Corporation, the Coulter Foundation Translational Partnership, and the Edward N. and Della L. Thome Memorial Foundation, Award in Age-Related Macular Degeneration Research.

current job

AsclepiX Therapeutics
AsclepiX Therapeutics

organization founded

1

Aleksander Popel

Employee Profiles
4

Amir Shojaei

Chief Scientific Officer, EVP-Clinical Development

Wendy Perrow

Wendy Perrow

CEO

Aleksander Popel

Aleksander Popel

Co-Founder & CSO

Jordan J. Green

Jordan J. Green

CTO & Co-Founder

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range